Pharmacological inhibition of the transcription factor PU.1 in leukemia
Open accessThe DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
The transcription factor PU.1 is often impaired in patients with acute myeloid leukemia (AML). Here, we used AML cells that already had low PU.1 levels and further inhibited PU.1 using either RNA interference or, to our knowledge, first-in-class small-molecule inhibitors of PU.1 that we developed specifically to allosterically interfere with PU.1-chromatin binding through interaction with the DNA minor groove that flanks PU.1-binding motifs. These small molecules of the heterocyclic diamidine family disrupted the interaction of PU.1 with target gene promoters and led to downregulation of canonical PU.1 transcriptional targets. shRNA or small-molecule inhibition of PU.1 in AML cells from either PU.1lo mutant mice or human patients with AML-inhibited cell growth and clonogenicity and induced apoptosis. In murine and human AML (xeno)transplantation models, treatment with our PU.1 inhibitors decreased tumor burden and resulted in increased survival. Thus, our study provides proof of concept that PU.1 inhibition has potential as a therapeutic strategy for the treatment of AML and for the development of small-molecule inhibitors of PU.1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A very intriguing new prospect for fast antagonism of PU.1 activity is the discovery of small-molecule inhibitors, some of which are highly potent and specific at blocking PU.1 action in leukemia cells; however, these have not yet been tested for effects on normal T-cell development (89).”
From Mechanisms of Action of Hematopoietic Transcription Factor PU.1 in Initiation of T-Cell Development (2019) · cites this paper as [89]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a luminescence reduction of 11.8 ± 22.3% in the presence of the PU.1-motif intercalator DB2313 (Antony-Debré et al., 2017; Munde et al., 2014; P ≤ 0.0001; Table S5).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Antony-Debré et al., 2017
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 2×
“was performed with gene sets from the Molecular Signatures Database (56, 57) and from the PU.”
MethodGenomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Margolin, A. A., Nemenman, I., Basso, K., Wiggins, C., Stolovitzky, G., Favera, R. D., & Califano, A. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-s1-s7 · Cited by 2,420
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1075 · Cited by 2,283
Margolin, A. A., Nemenman, I. M., Basso, K., Wiggins, C. H., Stolovitzky, G. A., Favera, R. D., & Califano, A. (2006) · BMC Bioinformatics · doi:10.7916/d8g15zbp · Cited by 2,246
Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532 · cited 1×
“1 is important for myeloid and lymphoid differentiation (13, 14), as well as hematopoietic stem cell (HSC) maintenance (15, 16).”
BackgroundReverse engineering of regulatory networks in human B cells
Basso, K., Margolin, A. A., Stolovitzky, G., Klein, U., Dalla-Favera, R., & Califano, A. (2005) · Nature Genetics · doi:10.1038/ng1532 · Cited by 1,404
Kim, J. H., Lee, S.-R., Li, L.-H., Park, H.-J., Park, J.-H., Lee, K. Y., Kim, M.-K., Shin, B. A., & Choi, S.-Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018556 · Cited by 1,338 · cited 1×
“was linked by a sequence encoding a self-cleaving 2A peptide (53).”
BackgroundTargeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130 · cited 1×
“1 is important for myeloid and lymphoid differentiation (13, 14), as well as hematopoietic stem cell (HSC) maintenance (15, 16).”
BackgroundBright and stable near-infrared fluorescent protein for in vivo imaging
Filonov, G. S., Piatkevich, K. D., Ting, L.-M., Zhang, J., Kim, K., & Verkhusha, V. V. (2011) · Nature Biotechnology · doi:10.1038/nbt.1918 · Cited by 688
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568 · cited 1×
“1 is distinguishable from other paralogs by the former’s strong preference for AT-rich sequences upstream of the 5′-GGAA-3′ consensus (27).”
BackgroundAcute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G. (2004) · Nature Genetics · doi:10.1038/ng1361 · Cited by 506 · cited 5×
“1 URE+/–Msh2–/– leukemia cells (17, 18) were cul-”
BackgroundInfluentialIwasaki, H., Somoza, C., Shigematsu, H., Duprez, E. A., Iwasaki-Arai, J., Mizuno, S.-I., Arinobu, Y., Geary, K., Zhang, P., Dayaram, T., et al. (2005) · Blood · doi:10.1182/blood-2005-03-0860 · Cited by 433 · cited 3×
“1 is important for myeloid and lymphoid differentiation (13, 14), as well as hematopoietic stem cell (HSC) maintenance (15, 16).”
BackgroundZhang, D.-E., Hetherington, C. J., Chen, H.-M., & Tenen, D. G. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.373-381.1994 · Cited by 411 · cited 2×
“1 positively regulates CSF1R and JUNB and autoregulates itself, whereas it represses E2F1 (12, 16, 36, 37).”
BackgroundReverse engineering cellular networks
Margolin, A. A., Wang, K., Lim, W. K., Kustagi, M., Nemenman, I., & Califano, A. (2006) · Nature Protocols · doi:10.1038/nprot.2006.106 · Cited by 379
A new pattern for helix–turn–helix recognition revealed by the PU.l ETS–domain–DNA complex
Kodandapani, R., Pio, F., Ni, C.-Z., Piccialli, G., Klemsz, M., McKercher, S., Maki, R. A., & Ely, K. R. (1996) · Nature · doi:10.1038/380456a0 · Cited by 315
Mizuki, M., Schwäble, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Böhmer, F. D., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1677 · Cited by 298 · cited 4×
“1 levels have been described in FLT3–internal tandem duplication (FLT3-ITD) (3), RUNX1-ETO (4), and promyelocytic leukemia (5), representing 24%, 7%, and 13% of all AMLs, respectively (cancer.”
BackgroundInfluentialEspinosa, J. M., Verdun, R. E., & Emerson, B. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00359-9 · Cited by 256 · cited 1×
“experiments were performed as previously described (54, 55), except”
MethodVangala, R. K., Heiss-Neumann, M. S., Rangatia, J. S., Singh, S. M., Schoch, C., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Blood · doi:10.1182/blood-2002-04-1288 · Cited by 245 · cited 4×
“1 levels have been described in FLT3–internal tandem duplication (FLT3-ITD) (3), RUNX1-ETO (4), and promyelocytic leukemia (5), representing 24%, 7%, and 13% of all AMLs, respectively (cancer.”
BackgroundInfluentialHeterozygous PU.1 mutations are associated with acute myeloid leukemia
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., Hiddemann, W., Ito, Y., & Tenen, D. G. (2002) · Blood · doi:10.1182/blood.v100.3.998 · Cited by 243
Antiparasitic compounds that target DNA
Wilson, W. D., Tanious, F. A., Mathis, A., Tevis, D., Hall, J. E., & Boykin, D. W. (2008) · Biochimie · doi:10.1016/j.biochi.2008.02.017 · Cited by 216 · cited 1×
“Classical heterocyclic diamidines, typified by furamidine (DB75), are highly selective and potent ligands for AT-rich DNA, a feature responsible for their success as inhibitors of kinetoplast DNA in trypanosomiasis (25, 26).”
BackgroundSelf-citationMueller, B. U., Pabst, T., Fos, J., Petkovic, V., Fey, M. F., Asou, N., Buergi, U., & Tenen, D. G. (2006) · Blood · doi:10.1182/blood-2005-07-3068 · Cited by 207 · cited 2×
“1 levels have been described in FLT3–internal tandem duplication (FLT3-ITD) (3), RUNX1-ETO (4), and promyelocytic leukemia (5), representing 24%, 7%, and 13% of all AMLs, respectively (cancer.”
Background(1995) · PubMed · Cited by 206
Nguyen, B., Tanious, F. A., & Wilson, W. D. (2007) · Methods · doi:10.1016/j.ymeth.2006.09.009 · Cited by 203 · cited 1×
“1, following our biosensor surface plasmon resonance (SPR) procedure (29, 30).”
BackgroundSelf-citationRole of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
Schneider, R. K., Ademà, V., Heckl, D., Järås, M., Mallo, M., Lord, A. M., Chu, L. P., McConkey, M. E., Kramann, R., Mullally, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.08.001 · Cited by 188 · cited 1×
“Cells with already reduced levels of CSNK1A were more sensitive to CSNK1A pharmacological inhibition than were cells with normal levels (44).”
BackgroundEssential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells
Steidl, U., Rosenbauer, F., Verhaak, R. G. W., Gu, X., Ebralidze, A., Otu, H. H., Klippel, S., Steidl, C., Bruns, I., Costa, D. B., et al. (2006) · Nature Genetics · doi:10.1038/ng1898 · Cited by 184 · cited 6×
“1 positively regulates CSF1R and JUNB and autoregulates itself, whereas it represses E2F1 (12, 16, 36, 37).”
BackgroundInfluentialSelf-citationLavallée, V.-P., Baccelli, I., Krosl, J., Wilhelm, B., Barabé, F., Gendron, P., Boucher, G., Lemieux, S., Marinier, A., Meloche, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3371 · Cited by 172
Staber, P. B., Zhang, P., Ye, M., Welner, R. S., Nombela-Arrieta, C., Bach, C., Kerenyi, M., Bartholdy, B. A., Zhang, H., Alberich-Jordà, M., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.007 · Cited by 158 · cited 4×
“1 is important for myeloid and lymphoid differentiation (13, 14), as well as hematopoietic stem cell (HSC) maintenance (15, 16).”
BackgroundInfluentialSelf-citationCarvajal, L. A., Hamard, P.-J., Tonnessen, C., & Manfredi, J. J. (2012) · Genes & Development · doi:10.1101/gad.184911.111 · Cited by 151 · cited 1×
“experiments were performed as previously described (54, 55), except”
MethodSelf-citationSynthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans
Das, B. P., & Boykin, D. W. (1977) · Journal of Medicinal Chemistry · doi:10.1021/jm00214a014 · Cited by 141 · cited 1×
“, DB75 [furamidine] and derivatives for trypanosomiasis) have been established in the context of other clinical applications (46, 47).”
BackgroundSelf-citationSoeiro, M. N. C., Werbovetz, K. A., Boykin, D. W., Wilson, W. D., Wang, M. Z., & Hemphill, A. F. (2013) · Parasitology · doi:10.1017/s0031182013000292 · Cited by 128 · cited 1×
“Classical heterocyclic diamidines, typified by furamidine (DB75), are highly selective and potent ligands for AT-rich DNA, a feature responsible for their success as inhibitors of kinetoplast DNA in trypanosomiasis (25, 26).”
BackgroundSelf-citationWill, B., Vogler, T. O., Narayanagari, S., Bartholdy, B., Todorova, T. I., da Silva Ferreira, M., Chen, J., Yu, Y., Mayer, J., Barreyro, L., et al. (2015) · Nature Medicine · doi:10.1038/nm.3936 · Cited by 127 · cited 2×
“DB2115 and DB2313 were selected itself; how ever, it leads to myeloid bias in (preleukemic) stem cells and MDS and AML development in combination with cooperating events (18).”
BackgroundSelf-citationGuibal, F. C., Alberich-Jorda, M., Hirai, H., Ebralidze, A., Levantini, E., Di Ruscio, A., Zhang, P., Santana-Lemos, B. A., Neuberg, D., Wagers, A. J., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182071 · Cited by 126 · cited 1×
“(43) and further separated the cell populations into the myeloblast/ promyelocyte-metamyelocyte/mature stages (Supplemental Figure 6C).”
BackgroundWenzler, T., Boykin, D. W., Ismail, M. A., Hall, J. E., Tidwell, R. R., & Brun, R. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00225-09 · Cited by 124 · cited 1×
“, DB75 [furamidine] and derivatives for trypanosomiasis) have been established in the context of other clinical applications (46, 47).”
BackgroundSelf-citationSteidl, U., Steidl, C., Ebralidze, A., Chapuy, B., Han, H.-J., Will, B., Rosenbauer, F., Becker, A., Wagner, K., Koschmieder, S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30525 · Cited by 114 · cited 1×
“1 expression, has been described in AML with complex karyotype (11), and a study on highly purified stem cells from patients with AML showed reduced PU.”
BackgroundSelf-citationA small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice
Illendula, A., Pulikkan, J. A., Zong, H., Grembecka, J., Xue, L., Sen, S., Zhou, Y., Boulton, A., Kuntimaddi, A., Gao, Y., et al. (2015) · Science · doi:10.1126/science.aaa0314 · Cited by 113
Mechanisms of in vivo binding site selection of the hematopoietic master transcription factor PU.1
Pham, T.-H., Minderjahn, J., Schmidl, C., Hoffmeister, H., Schmidhofer, S., Chen, W., Längst, G., Benner, C., & Rehli, M. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt355 · Cited by 102 · cited 1×
“1 is conferred through additional contacts with the minor groove of adjacent AT-rich tracks (24).”
BackgroundSzymczyna, B. R., & Arrowsmith, C. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004294200 · Cited by 99
Visualizing PU.1 activity during hematopoiesis
Back, J., Allman, D., Chan, S., & Kastner, P. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.12.010 · Cited by 97 · cited 2×
“1-GFP–knockin reporter mouse model (38) led to a decrease in GFP reporter expression after treatment with DB1976, DB2115, or DB2313, further confirming a direct effect of the compounds on PU.”
Small-molecule Binding to the DNA Minor Groove Is Mediated by a Conserved Water Cluster
Wei, D., Wilson, W. D., & Neidle, S. (2012) · Journal of the American Chemical Society · doi:10.1021/ja308952y · Cited by 81 · cited 1×
“The λB-bound complex showed the expected binding mode, including the typical water-mediated contacts between the 2 diamidiniumsand the DNA backbone (Supplemental Figure 2) (33).”
BackgroundSelf-citationMunde, M., Wang, S., Kumar, A., Stephens, C. E., Farahat, A. A., Boykin, D. W., Wilson, W. D., & Poon, G. M. K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt955 · Cited by 68 · cited 21×
“Treatment with compounds led to a profound decrease in the growth of PU.1 URE–/– AML cells (IC50 for DB2115: 3.4 μM < IC50 for DB2313: 7.1 μM < IC50 for DB1976: 105 μM), while showing little effect on normal hematopoietic cells at similar concentrations (calculated IC50 for DB2115: 192 μM; DB2313: 240 μM; DB1976: 334…”
BackgroundMethodInfluentialSelf-citationWang, S., Poon, G. M. K., & Wilson, W. D. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2877-4_20 · Cited by 52 · cited 1×
“Immobilized λB DNA was loaded to greater than 95% capacity and then titrated with graded concentrations of each compound (32).”
MethodSelf-citationMatthews, C. P., Birkholz, A. M., Baker, A. R., Perella, C. M., Beck, G. R., Young, M. R., & Colburn, N. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-0522 · Cited by 46 · cited 2×
“was performed with gene sets from the Molecular Signatures Database (56, 57) and from the PU.”
MethodDesigned Compounds for Recognition of 10 Base Pairs of DNA with Two AT Binding Sites
Liu, Y., Chai, Y., Kumar, A., Tidwell, R. R., Boykin, D. W., & Wilson, W. D. (2012) · Journal of the American Chemical Society · doi:10.1021/ja211628j · Cited by 42 · cited 21×
“Treatment with compounds led to a profound decrease in the growth of PU.1 URE–/– AML cells (IC50 for DB2115: 3.4 μM < IC50 for DB2313: 7.1 μM < IC50 for DB1976: 105 μM), while showing little effect on normal hematopoietic cells at similar concentrations (calculated IC50 for DB2115: 192 μM; DB2313: 240 μM; DB1976: 334…”
InfluentialSelf-citationGuo, P., Paul, A., Kumar, A., Farahat, A. A., Kumar, D., Wang, S., Boykin, D. W., & Wilson, W. D. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201603422 · Cited by 40 · cited 3×
“After synthesis, DB1976, DB2115, DB2313, and DB2457 were dissolved in sterile water and stored at –20°C. Mice.”
Self-citationPharmacologic efficacy of PU.1 inhibition by heterocyclic dications: a mechanistic analysis
Stephens, D. C., Kim, H. M., Kumar, A., Farahat, A. A., Boykin, D. W., & Poon, G. M. K. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw229 · Cited by 38 · cited 1×
“4 nM, in agreement with solution fluorescence anisotropy measurements (31).”
BackgroundSelf-citationEisenbeis, C. F., Singh, H., & Storb, U. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6452-6461.1993 · Cited by 38 · cited 1×
“1 sites, using the λB motif of the murine Igλ2-4 enhancer (5′-ATAAAAGGAAGTG-3′) (28) as a model.”
MethodThe Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells
Staber, P. B., Zhang, P., Ye, M., Welner, R. S., Levantini, E., Di Ruscio, A., Ebralidze, A. K., Bach, C., Zhang, H., Zhang, J., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550855 · Cited by 36 · cited 1×
“1 expression or activity is present in more than 50% of patients with AML and is associated with a specific transcriptional and epigenetic program (19, 20).”
BackgroundELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO
Lausen, J., Liu, S., Fliegauf, M., Lübbert, M., & Werner, M. H. (2005) · Oncogene · doi:10.1038/sj.onc.1209181 · Cited by 34
Transcriptomic profiling identifies a PU.1 regulatory network in macrophages
Weigelt, K., Lichtinger, M., Rehli, M., & Langmann, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.067 · Cited by 33 · cited 5×
“We compared the differentially expressed genes upon PU.1 inhibitor treatment of PU.1 URE–/– AML cells with publicly available data in which the PU.1-regulatory transcriptional network had been identified by tamoxifen-mediated induction of PU.1 expression in engineered PU.1-null immature hematopoietic cells (PUER cells…”
BackgroundMethodInfluentialHeterozygous deletion of the PU.1 locus in human AML
Bonadies, N., Pabst, T., & Mueller, B. U. (2010) · Blood · doi:10.1182/blood-2009-03-212225 · Cited by 33 · cited 2×
“1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.”
BackgroundMunde, M. M., Poon, G. M. K., & Wilson, W. D. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.02.010 · Cited by 31 · cited 1×
“1 by novel heterocyclic diamidines, which are derivatives of clinically tested compounds such as furamidine (22, 23).”
BackgroundSelf-citationLentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts
Durual, S., Rideau, A., Ruault-Jungblut, S., Cossali, D., Beris, P., Piguet, V, & Matthes, T. (2007) · Leukemia · doi:10.1038/sj.leu.2404645 · Cited by 30
PU.1 Binds to a Distal Regulatory Element That Is Necessary for B Cell-Specific Expression of CIITA
Yoon, H., & Boss, J. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000079 · Cited by 29
Sive, J. I., Basilico, S., Hannah, R., Kinston, S. J., Calero-Nieto, F. J., & Göttgens, B. (2016) · Leukemia · doi:10.1038/leu.2015.172 · Cited by 17 · cited 6×
“To identify genes directly regulated by PU.1, we used the PU.1 ChIP-seq data obtained from GSE63317 (GSM1545739) (20).”
BackgroundMethodInfluential
Research works printed but not linked: 1
- Nanjunda RM, Munde M, Liu M, Wilson WD. Real-time monitoring of nucleic acid interactions with biosensor surface plasmon resonance. In: Wanunu Y, ed. Methods for Studying DNA/ Drug Interactions. Boca Raton, FL: CRC Press; 2011:92-122.
Cited by
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Targeting Transcription Factors for Cancer Treatment
Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 352
PTEN Tumor-Suppressor: The Dam of Stemness in Cancer
Luongo, F., Colonna, F., Calapà, F., Vitale, S., Fiori, M. E., & De Maria, R. (2019) · Cancers · doi:10.3390/cancers11081076 · Cited by 189
“Of note, replacing rapamycin, with NVP-BEZ235, a dual inhibitor of PI3K and mTOR, resulted in cell cycle arrest and reduced L-CSCs compartment [186].”
BackgroundInfluentialViny, A. D., Bowman, R. L., Liu, Y., Lavallée, V.-P., Eisman, S. E., Xiao, W., Durham, B. H., Navitski, A., Park, J., Braunstein, S., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.08.003 · Cited by 158
“role in determining hematopoietic lineage commitment (Antony-Debre et al., 2017; Will et al., 2015).”
An overview of recent advances in duplex DNA recognition by small molecules
Bhaduri, S., Ranjan, N., & Arya, D. P. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.93 · Cited by 162
Metadata
- Authors
- Antony-Debré, I., Paul, A., Leite, J., Mitchell, K., Kim, H. M., Carvajal, L. A., Todorova, T. I., Huang, K., Kumar, A., Farahat, A. A., Bartholdy, B., Narayanagari, S.-R., Chen, J., Ambesi-Impiombato, A., Ferrando, A. A., Mantzaris, I., Gavathiotis, E., Verma, A., Will, B., Boykin, D. W., Wilson, W. D., Poon, G. M. K., & Steidl, U.
- Affiliations
- Georgia State University (US)
- Albert Einstein College of Medicine (US)
- Mansoura University (EG)
- Columbia University (US)
- Corresponding author
- Steidl, Ulrich
- ORCID
- Paul, Ananya
- Mitchell, Kelly
- Kim, Hye Mi
- Carvajal, Luis A.
- Todorova, Tihomira I.
- Huang, Kenneth
- Kumar, Arvind
- Farahat, Abdelbasset A.
- Bartholdy, Boris
- Narayanagari, Swathi-Rao
- Chen, Jiahao
- Ambesi-Impiombato, Alberto
- Ferrando, Adolfo A.
- Mantzaris, Ioannis
- Gavathiotis, Evripidis
- Verma, Amit
- Will, Britta
- Wilson, W. David
- Poon, Gregory M.K.
- Steidl, Ulrich
- Venue
- Journal of Clinical Investigation
- Published
- 2017-10-30
- Volume
- 127
- Issue
- 12
- Pages
- 4297-4313
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5707147
- OpenAlex
- W2766367793
- Cited by
- 120
- References
- 58
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 10 · 2023: 16 · 2022: 19 · 2021: 11 · 2020: 15 · 2019: 17 · 2018: 11 · 2017: 2
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Leukemia & Lymphoma Society (6504-17)
- Henry and Marilyn Taub Foundation (Taub Foundation Grants Program for MDS Research)
- National Institutes of Health (R01CA217092)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- PU.1, acute myeloid leukemia, transcription factor inhibition, small molecule inhibitors, allosteric inhibition, DNA minor groove, chromatin binding, RNA interference, apoptosis, therapeutic target
- MeSH terms
- THP-1 Cells, Proto-Oncogene Protein Spi-1, Allosteric Regulation, Animals, Chromatin, Humans, Mice, Transgenic, Pentamidine, Proto-Oncogene Proteins, Leukemia, Myeloid, Acute, Trans-Activators, Apoptosis, Xenograft Model Antitumor Assays, RNA Interference, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.